Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

Active, not recruitingOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

January 13, 2025

Study Completion Date

October 31, 2025

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Alpelisib

Patients will receive standard of care alpelisib

DEVICE

FreeStyle Libre 2 Continuous Glucose Monitor

All patients will wear Abbott FreeStyle Libre 2 system to obtain CGM data (glucoses measured every minute for 14 days). CGM monitors will be placed at least 10 days prior to starting alpelisib and continue CGM for at least 3 months while taking alpelisib.

Trial Locations (1)

55426

HealthPartners Cancer Research Center, Saint Louis Park

All Listed Sponsors
lead

HealthPartners Institute

OTHER

NCT06083038 - Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib | Biotech Hunter | Biotech Hunter